<div id="readability-page-1"><div><p>Ono Pharmaceutical Co., Ltd. announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. Summary of Data and Findings from the 2-year results of the MOTION Phase 3 Study Methods: The global Phase 3 MOTION study (NCT05059262) aims to evaluate the efficacy and safety of vimseltinib for the treatment of TGCT in cases where surgical remove of the tumor is not an options. The study consists of two parts.</p><p>In Part 1, eligible study participants were assigned to receive either vimseltinib or matching placebo for 24 weeks. Participants assigned to placebo in Part 1 had the option to receive vimseltinib for Part 2. Part 2 was a long-term treatment phase in which all participants received open-label vimseltinib. Patients received vimseltinib 30 mg twice weekly in all periods.</p><p>Objective response rate (ORR) based on best overall response was assessed by independent radiological review (IRR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) and per Tumor Volume Score (TVS). Duration of response (DOR) and safety were also evaluated.</p></div></div>

小野制药(ADR)

<p>小野制药 (ADR) 将在 2025 年欧洲医学肿瘤学会大会上展示其 MOTION III 期研究中 vimseltinib 治疗腱鞘巨细胞瘤（TGCT）两年的疗效和安全性结果。该研究评估了 vimseltinib 在无法进行手术切除的患者中的有效性，参与者在两部分研究中接受药物或安慰剂。结果包括基于独立评审的客观反应率和安全性评估</p>

Ono Pharmaceutical Co., Ltd. Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study ofromVIMZA in Patients with Tenosynovial Giant Cell Tumor at the European Society for Medical Oncology Congress 2025

小野制药有限公司在 2025 年欧洲肿瘤医学学会大会上公布了 VIMZA 用于腱鞘巨细胞瘤患者的 MOTION 三期研究的两年疗效和安全性结果